+34 620 10 75 37info@nanbiosis.com

Posts Taged diagnosis-test

Prof. Pilar Marco, in the program “Meridiano Turing” of RTVE explains the COVID-19 tests.

The last edition of the program “Meridiano Turing” of RTVE interviews Maria Pilar Marco Head of CIBER-BBN and IQAC-CSIC group Nb4D and NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS), Cesar Fernández (Head of the Chemical Transducers Group at IMB-CNM, CSIC) and María Cruz Minguillón (EGAR group at IDAEA)

Pilar Marco y César Fernández, the authors of the block of the CSIC’s report entitled “Containment and diagnosis“, explain wich is the best way to diagnose COVID and how reliable are the tests in this moment.

What is needed is to detect an infection -says Pilar Marco- is viral material and we have two types of tests to detect viral material:
– Those that detect the viral RMA, which is the genetic material of the virus. These test known as “PCR”, were the first to be used and are quite reliable PCR is a technology that expands the genetic material, making many copies what makes it possible to detect the viral material with very low viral load
– And during the month of September have became famous what are known as the “antigen tests” (they also came out at the beginning, but they were of low quality). These tests do not detect the genetic material but the structural proteins of the virus.

Serological tests should not be used to diagnose an infection because they do not detect the virus, what they detect is the reaction that the host has in the presence of an infection, that is, the antibodies that our body produces to defend itself against the infection and this occurs from the first moment but is not detectable until practically seven days after being infected. Therefore serological tests have limited utility to diagnose the infection, they serve to monitor the evolution and immunological status of the patient, if he is producing antibodies against the virus and how it evolves The virus remains elevated for months, but it does not mean that if you have had the disease and the rsults fo serological tests are negative, you are not prepared to face the virus, since we have memory cells that will surely produce antibodies again.

Cesar Fernández explains that the sample is the same in PCR and antigen tests, but the time it takes to obtain an answer is different. Both type of tests are recommended depending on the situation and the environment in which they are used, PCR tests have been used more massively and are more reliable in the sense that they let out much fewer positives, the number of false negatives they provide is very low, but they are also more expensive tests and need more time from the moment the sample is taken until the result is obtained (minimum 24 hours) since they are carried out in clinical analysis laboratories. The antigen tests can be carried out in 15-30 minutes in the place where the sample is taken and their cost is very low compared to that of the PCR, which is why they are very useful for screening studies of the levels infection that may exist in a community. Currently, work is being done on carrying out the antigen tests in saliva, this would facilitate the taking of samples and would not generate practically social rejection. Studies are also being done on the use of nasal smears in which the sample is taken at the beginning of the nasal cavity, resulting in much less annoying. Antigen tests due to their low cost and ease use open the possibility of performing in a very repetitive way.

Regarding the measurement of viral load, it is given by the PCR, while in the antigen tests the detection is visual, a colored line appears, similar to the pregnancy tests, with greater or lesser intensity, with which the information they give on viral load is semi-quantitative, that is, the interpretation is quite subjective.
The viral load of the disease appears a few days before sinthoms are shown (the peak is two days before) and can be spread to other people. This also occurs with asymptomatic infected people, with the only difference that, after this peak, the viral load falls very quickly and the disease does not appear.

Read More

New test trials to diagnose Covid 19: Ramon Martinez, Scientific Director of CIBER-BBN is interviewed by Spanish Television

Ramón Martinez, Scientific Director of CIBER-BBN and NANBIOSIS unit 26 NMR: Biomedical Applications II is interviewed by Spanish Television about the research he is coordinating at the Polytechnic University of Valencia to develop new tests as an alternative to PCR.

Dr. Elena Aznar CIBER researcher at IQMA-IDM-UPV group explains how work these test that allow to diagnose quickly, easily, reliably and cheaply if a person is or has been infected by the SARS-COV-2 virus. Ramón Martínez Máñez, leader of the project, reports on the point where the investigation is, as well as the difference of these tests with PCR or antigen tests. These tests implement a technology of the research group that has already been used for other pathogens and that they try to adapt to the COVID virus. “My impression – explains Dr. Martínez – is that the time will come when these tests can be sold in pharmacies and can be used by the users themselves. At the moment we have to see if they work in patient samples and then adapt it so that be a marketable kit by an interested company

The interview can be whatched here:

Read More

New updated version of the CSIC report on COVID-19

The report by Spanish Higher Council for Scientific Research (CSIC) summarizng the most relevant scientific results on the Covid-19 pandemic.  “A global vision of the Covid-19 pandemic: What we know and what we are investigating from CSIC”, has just published its version number 4.

This report is structured in five blocks: prevention, disease, containment and diagnosis, treatment and vaccines, and global impact.

The containment and diagnosis block describes how the virus is transmitted in the air indoors and the analysis of wastewater as a system for early detection of SARS-CoV-2 is explained. In addition, the importance of diagnosis in the face of the pandemic is underlined and the different types of detection tests available and the diagnostic strategies to control the spread of the infection are detailed. The CIBER-BBN/IQAC-CSIC Nb4D research group and its research platform NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS) takes and important role in this block.

Pilar Marco, Scientific Director of CAbS is co-author, toguether with Cesar Fernandez (IBM-CNM-CSIC) of the chapter 3.4 “The role of the Diagnosis in the face of pandemic” wich provides information on the types of tests, how to perform and how to use them for the different purposes for which  diagnosis is an indispensable tool. “From a broad perspective, we can  distinguish between two types of tests: A. Viral tests: they detect the SARS-CoV-2 virus, include the well-known PCR (Polymerase Chain Reaction) or molecular tests, which detect the genetic material virus B. Test that detect the response of the human body to infection. They include so-called “serological tests, which detect antibodies produced by the patient’s immune system, although other types of biomarkers can also be detected.”

For further information and access to report: http://hdl.handle.net/10261/218312 

Read More